Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of deucravacitinib in participants with alopecia areata was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• Deucravacitinib (deucravacitinib)
• Sotyktu (Deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Alopecia Areata | Phase 2 | Status: TERMINATED | Results posted: 2025-02-28